Biomarkers can be used to screen healthy individuals for possible disease. General results have shown dynamic changes in differentially expressed circulating RNAs specific to the histology and stage of lung carcinoma. The largest number of differentially expressed RNAs has been identified approximately 7 years before diagnosis in early stage lung cancer. The data to date show the potential for lung cancer screening and suggest improved treatment and prognosis.
Diagnostic biomarkers can be used for differential diagnosis, e.g. whether a recurrence of breast cancer is plausible (CA 12-3). High CA 15-3 values alone do not provide enough evidence. They are only significant if the value of a “CA 15-3 tumour” increases or worsens during therapy. There is a correlation between the level of CEA and/or CA 15-3 and the progression of the tumour related illness. Thus, if there is a moderate increase, it can be detected early, and physicians can discuss personalised therapy.
The object of ICHORtec research and development is to use the FMB® method to prevent measurement artefacts in the detection of biomarkers and to increase sensitivity. Through direct access to the molecular structure, a significant increase in sensitivity and specificity can be expected.